Last reviewed · How we verify
Paracetamol fast dissolution suspension — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Paracetamol fast dissolution suspension (Paracetamol fast dissolution suspension) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Paracetamol fast dissolution suspension TARGET | Paracetamol fast dissolution suspension | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Paracetamol fast dissolution suspension CI watch — RSS
- Paracetamol fast dissolution suspension CI watch — Atom
- Paracetamol fast dissolution suspension CI watch — JSON
- Paracetamol fast dissolution suspension alone — RSS
Cite this brief
Drug Landscape (2026). Paracetamol fast dissolution suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/paracetamol-fast-dissolution-suspension. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing